FDA new guidance on Multiple Endpoints in Clinical Trials
Failure to account for multiplicity when there are several clinical endpoints evaluated in a study can lead to false conclusions regarding the effects of the drug.
The regulatory concern regarding multiplicity arises principally in the evaluation of clinical trials intended to demonstrate effectiveness and support drug approval; however, this issue is important throughout the drug development process